UA26427A - Похідhі ксаhтиhу у вигляді суміші ізомерів або іhдивідуальhих ізомерів, що мають властивість аhтагоhіста адеhозиhу - Google Patents

Похідhі ксаhтиhу у вигляді суміші ізомерів або іhдивідуальhих ізомерів, що мають властивість аhтагоhіста адеhозиhу

Info

Publication number
UA26427A
UA26427A UA5011448A UA5011448A UA26427A UA 26427 A UA26427 A UA 26427A UA 5011448 A UA5011448 A UA 5011448A UA 5011448 A UA5011448 A UA 5011448A UA 26427 A UA26427 A UA 26427A
Authority
UA
Ukraine
Prior art keywords
isomers
derivatives
xahtich
adhesic
protector
Prior art date
Application number
UA5011448A
Other languages
English (en)
Russian (ru)
Inventor
Ульріке Кюфнер-Мюль
Ульрике Кюфнер-Мюль
Карл-Гейнц Вебер
Герхард Вальтер
Вернер Странскі
Вернер Странски
Гельмут Ейзінгер
Гельмут Эйзингер
Гюнтер Шінгнітц
Гюнтер Шингнитц
Франц-Йозеф Кун
Еріх ЛЕР
Эрих ЛЕР
Original Assignee
Берінгер Інгельгайм Кг
Берингер Ингельгайм Кг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Берінгер Інгельгайм Кг, Берингер Ингельгайм Кг filed Critical Берінгер Інгельгайм Кг
Publication of UA26427A publication Critical patent/UA26427A/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Предметом винаходу є похідні ксантину загальної формули де R1 і R2 – нижчий алкіл; R3 – залишок з групи, яка включає тетрагідрофуранон, тіофен, дитіоланіл, дитіаніл, фуран.
UA5011448A 1988-12-22 1989-12-21 Похідhі ксаhтиhу у вигляді суміші ізомерів або іhдивідуальhих ізомерів, що мають властивість аhтагоhіста адеhозиhу UA26427A (uk)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3843117A DE3843117A1 (de) 1988-12-22 1988-12-22 Neue xanthinderivate mit adenosin-antagonistischer wirkung

Publications (1)

Publication Number Publication Date
UA26427A true UA26427A (uk) 1999-08-30

Family

ID=6369764

Family Applications (1)

Application Number Title Priority Date Filing Date
UA5011448A UA26427A (uk) 1988-12-22 1989-12-21 Похідhі ксаhтиhу у вигляді суміші ізомерів або іhдивідуальhих ізомерів, що мають властивість аhтагоhіста адеhозиhу

Country Status (32)

Country Link
US (4) US5175291A (uk)
EP (1) EP0374808B1 (uk)
JP (1) JP2565576B2 (uk)
KR (1) KR0165666B1 (uk)
AT (1) ATE136897T1 (uk)
BG (1) BG61669B2 (uk)
BR (1) BR1100527A (uk)
CA (1) CA2006387C (uk)
CZ (1) CZ286230B6 (uk)
DD (1) DD290421A5 (uk)
DE (3) DE8817122U1 (uk)
DK (1) DK652689A (uk)
ES (1) ES2086313T3 (uk)
FI (1) FI96513C (uk)
GR (1) GR3019733T3 (uk)
HR (1) HRP940724A2 (uk)
HU (1) HU218674B (uk)
IE (1) IE74205B1 (uk)
IL (1) IL92829A (uk)
MX (1) MX9203618A (uk)
NO (1) NO173502C (uk)
NZ (1) NZ231901A (uk)
PH (2) PH31107A (uk)
PL (1) PL162877B1 (uk)
PT (1) PT92658B (uk)
RU (1) RU2057752C1 (uk)
SG (1) SG46380A1 (uk)
SI (1) SI8912423B (uk)
SK (1) SK719789A3 (uk)
UA (1) UA26427A (uk)
YU (1) YU47934B (uk)
ZA (1) ZA899881B (uk)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE8817122U1 (de) * 1988-12-22 1993-02-04 Boehringer Ingelheim Kg, 55218 Ingelheim Neue Xanthinderivate mit Adenosinantogenistischer Wirkung
JPH06102662B2 (ja) * 1989-09-01 1994-12-14 協和醗酵工業株式会社 キサンチン誘導体
US5290782A (en) * 1989-09-01 1994-03-01 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivatives
US5047534A (en) * 1990-03-26 1991-09-10 Merrell Dow Pharmaceuticals Inc. Selective adenosine receptor agents
DE4019892A1 (de) * 1990-06-22 1992-01-02 Boehringer Ingelheim Kg Neue xanthinderivate
CA2061544A1 (en) * 1991-02-25 1992-08-26 Fumio Suzuki Xanthine compounds
GB9111131D0 (en) * 1991-05-23 1991-07-17 Ici Plc Heterocyclic compounds
GB9111130D0 (en) * 1991-05-23 1991-07-17 Ici Plc Azole derivatives
DE69229257D1 (de) * 1991-11-08 1999-07-01 Kyowa Hakko Kogyo Kk Xanthinderivate zur Behandlung der Demenz
IT1260444B (it) * 1992-01-24 1996-04-09 Mario Brufani Derivati della 8-(1-amminocicloalchil)1,3-dialchilxantina, procedimenbto di preparazione e loro composizioni farmaceutiche antidepressive, nootropiche e psicostimolanti
US5336769A (en) * 1992-02-17 1994-08-09 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivatives
CA2093403C (en) * 1992-04-08 1999-08-10 Fumio Suzuki Therapeutic agent for parkinson's disease
US5484920A (en) * 1992-04-08 1996-01-16 Kyowa Hakko Kogyo Co., Ltd. Therapeutic agent for Parkinson's disease
WO1994003173A1 (de) * 1992-08-01 1994-02-17 Boehringer Ingelheim Kg Verwendung von 8-(3-oxocyclopentyl)-1,3-dipropyl-7h-purin-2,6-dion zur symptomatischen behandlung der zystischen fibrose
TW252044B (uk) * 1992-08-10 1995-07-21 Boehringer Ingelheim Kg
US5288721A (en) * 1992-09-22 1994-02-22 Cell Therapeutics, Inc. Substituted epoxyalkyl xanthines
JP2613355B2 (ja) * 1992-09-28 1997-05-28 協和醗酵工業株式会社 パーキンソン氏病治療剤
US5877179A (en) * 1992-09-29 1999-03-02 The United States Of America As Represented By The Department Of Health And Human Services Xanthines for identifying CFTR--binding compounds useful for activating chloride conductance in animal cells
DE4236331A1 (de) * 1992-10-28 1994-05-05 Boehringer Ingelheim Kg Synergistische Kombination
AU6087894A (en) * 1993-01-14 1994-08-15 Cell Therapeutics, Inc. Acetal or ketal substituted therapeutic compounds
WO1994019349A1 (en) * 1993-02-26 1994-09-01 Merrell Dow Pharmaceuticals Inc. Xanthine derivatives as adenosine a1 receptor antagonists
AU6781194A (en) * 1993-05-03 1994-11-21 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The 8-substituted 1,3,7-trialkyl-xanthine derivatives as a2-selective adenosine receptor antagonists
DE4316576A1 (de) * 1993-05-18 1994-11-24 Boehringer Ingelheim Kg Verbessertes Verfahren zur Herstellung von 1,3-Dipropyl-8-(3-Oxocyclopentyl)-xanthin
US5736528A (en) * 1993-10-28 1998-04-07 University Of Florida Research Foundation, Inc. N6 -(epoxynorborn-2-yl) adenosines as A1 adenosine receptor agonists
US5446046A (en) * 1993-10-28 1995-08-29 University Of Florida Research Foundation A1 adenosine receptor agonists and antagonists as diuretics
JP3769737B2 (ja) * 1994-03-30 2006-04-26 味の素株式会社 シクロプロパン誘導体及びその製造法
US5591776A (en) * 1994-06-24 1997-01-07 Euro-Celtique, S.A. Pheynl or benzyl-substituted rolipram-based compounds for and method of inhibiting phosphodiesterase IV
ATE247655T1 (de) * 1994-12-13 2003-09-15 Euro Celtique Sa Dreifachsubstituierte thioxanthine
WO1996018399A1 (en) * 1994-12-13 1996-06-20 Euro-Celtique, S.A. Aryl thioxanthines
US5864037A (en) 1996-06-06 1999-01-26 Euro-Celtique, S.A. Methods for the synthesis of chemical compounds having PDE-IV inhibitory activity
US5789416B1 (en) * 1996-08-27 1999-10-05 Cv Therapeutics Inc N6 mono heterocyclic substituted adenosine derivatives
US5786360A (en) 1996-11-19 1998-07-28 Link Technology Incorporated A1 adenosine receptor antagonists
EP1016407B1 (en) * 1997-09-05 2006-05-10 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivatives for treating brain ischemia
US6248746B1 (en) 1998-01-07 2001-06-19 Euro-Celtique S.A. 3-(arylalkyl) xanthines
DE19816857A1 (de) * 1998-04-16 1999-10-21 Boehringer Ingelheim Pharma Neue unsymmetrisch substituierte Xanthin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
CA2333947C (en) * 1998-06-01 2010-09-21 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compounds as adenosine a1 antagonist for male sterility
AU4980999A (en) 1998-07-10 2000-02-01 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The A3 adenosine receptor antagonists
US6025362A (en) * 1998-08-31 2000-02-15 Fukunaga; Atsuo F. Uses of xanthine compounds
US6576619B2 (en) 1999-05-24 2003-06-10 Cv Therapeutics, Inc. Orally active A1 adenosine receptor agonists
US6545002B1 (en) * 1999-06-01 2003-04-08 University Of Virginia Patent Foundation Substituted 8-phenylxanthines useful as antagonists of A2B adenosine receptors
GEP20043267B (en) 1999-11-12 2004-06-25 Biogen Inc Us Adenosine Receptor Antagonists, Methods of Making and Using the Same
PT1230243E (pt) * 1999-11-12 2009-06-12 Biogen Idec Inc Policicloalquilpurinas como antagonistas dos receptores da adenosina
US7087589B2 (en) 2000-01-14 2006-08-08 The United States Of America As Represented By The Department Of Health And Human Services Methanocarba cycloakyl nucleoside analogues
US20020115635A1 (en) * 2001-02-21 2002-08-22 Pnina Fishman Modulation of GSK-3beta activity and its different uses
US7125993B2 (en) * 2001-11-09 2006-10-24 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US20080318983A1 (en) * 2001-11-09 2008-12-25 Rao Kalla A2b adenosine receptor antagonists
IL161867A0 (en) 2001-11-09 2005-11-20 Cv Therapeutics Inc A2b adenosine receptor antagonists
US7317017B2 (en) 2002-11-08 2008-01-08 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US6977300B2 (en) * 2001-11-09 2005-12-20 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
WO2004009594A2 (en) * 2002-07-19 2004-01-29 Aryx Therapeutics Xanthine derivatives having adenosine a1-receptor antagonist properties
CA2516250A1 (en) 2003-02-19 2004-09-02 Endacea, Inc. A1 adenosine receptor antagonists
US20040229901A1 (en) * 2003-02-24 2004-11-18 Lauren Otsuki Method of treatment of disease using an adenosine A1 receptor antagonist
WO2004096228A1 (en) * 2003-04-25 2004-11-11 Novacardia, Inc. Method of improved diuresis in individuals with impaired renal function
US20060293312A1 (en) * 2003-04-25 2006-12-28 Howard Dittrich Method of improved diuresis in individuals with impaired renal function
DE60322748D1 (de) * 2003-05-06 2008-09-18 Cv Therapeutics Inc Xanthinderivate als a2b-adenosinrezeptorantagonisten
US7247639B2 (en) * 2003-06-06 2007-07-24 Endacea, Inc. A1 adenosine receptor antagonists
US20090068101A9 (en) * 2003-06-09 2009-03-12 Endacea, Inc. A1 Adenosine Receptor Antagonists
TW200507882A (en) * 2003-07-17 2005-03-01 Kyowa Hakko Kogyo Kk Solid formulations
US6847249B1 (en) * 2003-10-09 2005-01-25 Analog Devices, Inc. Highest available voltage selector circuit
JP2007532671A (ja) * 2004-04-16 2007-11-15 ノヴァカーディア，インク． アデノシンａ１受容体アンタゴニストおよびアルドステロン阻害剤を含む併用療法
CA2578702A1 (en) * 2004-09-01 2006-03-16 Cv Therapeutics, Inc. Method of wound healing using a2b adenosine receptor antagonists
JP2009540003A (ja) * 2006-06-16 2009-11-19 ノヴァカーディア，インク． Ａａ１ｒａの低頻度投与を含む腎機能の長期間にわたる改善
US8193200B2 (en) 2007-01-04 2012-06-05 University Of Virginia Patent Foundation Antagonists of A2B adenosine receptors for treatment of inflammatory bowel disease
WO2008121893A1 (en) * 2007-03-29 2008-10-09 Novacardia, Inc. Methods of treating heart failure and renal dysfunction in individuals with an adenosine a1 receptor antagonist
US20080242684A1 (en) * 2007-03-29 2008-10-02 Howard Dittrich Methods of administration of adenosine a1 receptor antagonists
AU2009230679B2 (en) * 2008-03-26 2013-07-18 Advinus Therapeutics Pvt. Ltd. Heterocyclic compounds as adenosine receptor antagonist
US8129862B2 (en) * 2009-10-23 2012-03-06 Analog Devices, Inc. Scalable highest available voltage selector circuit
WO2011055391A1 (en) * 2009-11-09 2011-05-12 Advinus Therapeutics Private Limited Substituted fused pyrimidine compounds, its preparation and uses thereof
EP2507241A1 (en) 2009-12-02 2012-10-10 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Methanocarba adenosine derivatives and dendrimer conjugates thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1201997A (en) * 1967-08-04 1970-08-12 Yissum Res Dev Co New substituted purines and purine derivatives
US3624215A (en) * 1970-06-25 1971-11-30 Abbott Lab 8-substituted theophyllines as anti-anxiety agents
US3624216A (en) * 1970-06-25 1971-11-30 Abbott Lab 8-substituted theophyllines as anti-inflammatory agents
DE3028273A1 (de) * 1980-07-25 1982-02-25 Fa. Dr. Willmar Schwabe, 7500 Karlsruhe Durch purinbasen substituierte 1.4;3.6-dianhydro-hexit-nitrate
ES517622A0 (es) * 1982-11-23 1983-12-16 Faes Procedimiento de preparacion de un nuevo espirodecano.
US4593095A (en) * 1983-02-18 1986-06-03 The Johns Hopkins University Xanthine derivatives
US4548939A (en) * 1984-10-01 1985-10-22 Janssen Pharmaceutica N. V. 1H-Indol-3-yl containing 1,3-dimethyl-1H-purine-2,6-diones
US4755517A (en) * 1986-07-31 1988-07-05 Warner-Lambert Company Derivatives of xanthine, pharmaceutical compositions and methods of use therefor
US5175290A (en) * 1988-09-16 1992-12-29 Marion Merrell Dow Inc. 8-(oxo-substituted cycloalkyl)xanthines
DE8817122U1 (de) * 1988-12-22 1993-02-04 Boehringer Ingelheim Kg, 55218 Ingelheim Neue Xanthinderivate mit Adenosinantogenistischer Wirkung
JPH06102662B2 (ja) * 1989-09-01 1994-12-14 協和醗酵工業株式会社 キサンチン誘導体
US5290782A (en) * 1989-09-01 1994-03-01 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivatives
US4957921A (en) * 1989-12-06 1990-09-18 Warner-Lambert Company Substituted cyclohexanols as central nervous system agents
DE69229257D1 (de) * 1991-11-08 1999-07-01 Kyowa Hakko Kogyo Kk Xanthinderivate zur Behandlung der Demenz

Also Published As

Publication number Publication date
YU47934B (sh) 1996-05-20
BR1100527A (pt) 2000-08-01
SK279525B6 (sk) 1998-12-02
JP2565576B2 (ja) 1996-12-18
KR0165666B1 (ko) 1999-01-15
HU896736D0 (en) 1990-02-28
DK652689A (da) 1990-06-23
PH31111A (en) 1998-02-23
NO895168L (no) 1990-06-25
EP0374808A3 (de) 1991-05-15
HUT52503A (en) 1990-07-28
DE58909657D1 (de) 1996-05-23
IL92829A (en) 1995-12-31
NO173502B (no) 1993-09-13
FI96513B (fi) 1996-03-29
YU242389A (en) 1991-10-31
SI8912423B (sl) 1998-12-31
PH31107A (en) 1998-02-23
NO173502C (no) 1993-12-22
CZ719789A3 (cs) 1999-10-13
PL282878A1 (en) 1992-03-09
IE894147L (en) 1990-06-22
PL162877B1 (pl) 1994-01-31
FI96513C (fi) 1996-07-10
HU218674B (hu) 2000-10-28
SI8912423A (sl) 1998-04-30
NZ231901A (en) 1993-12-23
EP0374808A2 (de) 1990-06-27
SK719789A3 (en) 1998-12-02
DE8817122U1 (de) 1993-02-04
MX9203618A (es) 1992-09-01
CA2006387A1 (en) 1990-06-22
RU2057752C1 (ru) 1996-04-10
SG46380A1 (en) 1998-02-20
CA2006387C (en) 2000-02-08
FI896117A0 (fi) 1989-12-20
ATE136897T1 (de) 1996-05-15
GR3019733T3 (en) 1996-07-31
HRP940724A2 (en) 1997-06-30
IE74205B1 (en) 1997-07-16
KR900009646A (ko) 1990-07-05
US5696124A (en) 1997-12-09
EP0374808B1 (de) 1996-04-17
PT92658B (pt) 1995-09-12
US5175291A (en) 1992-12-29
AU637990B2 (en) 1993-06-17
US5688802A (en) 1997-11-18
ES2086313T3 (es) 1996-07-01
DE3843117A1 (de) 1990-06-28
DD290421A5 (de) 1991-05-29
US5532368A (en) 1996-07-02
CZ286230B6 (cs) 2000-02-16
AU4707289A (en) 1990-06-28
DK652689D0 (da) 1989-12-21
JPH02247180A (ja) 1990-10-02
BG61669B2 (bg) 1998-02-27
NO895168D0 (no) 1989-12-21
PT92658A (pt) 1990-06-29
IL92829A0 (en) 1990-09-17
ZA899881B (en) 1991-08-28

Similar Documents

Publication Publication Date Title
UA26427A (uk) Похідhі ксаhтиhу у вигляді суміші ізомерів або іhдивідуальhих ізомерів, що мають властивість аhтагоhіста адеhозиhу
BG92804A (bg) 4-бензоилизоксазолови производни
HUP9802859A2 (hu) Acil-amino-szalicilsav-amid-származékok és alkalmazásuk peszticidként
ES2077138T3 (es) Derivados de aminocumarano, su produccion y su uso.
ES2053508T3 (es) Compuestos de acidos 3-pirrolidinil-tio-1-azabiciclo(3.2.0)hept-2-eno-2-carboxilicos.
ES2053609T3 (es) Derivados de urea inhibidores de lipoxigenasa.
NO963370L (no) Nye mercaptoacetylamido-1,3,4,5-tetrahydrobenzo[cÅazepin-3-on-disulfidderivater som er anvendbare som inhibitorer av enkefalinase og ACE
DK249089A (da) Benzamid-forbindelser, der er nyttige som protease-inhibitorer
PT81855B (pt) Processo de preparacao de arilciclobutilalquilaminas e de composicoes farmaceuticas que as contem
ES8506629A1 (es) Un procedimiento para preparar derivados de piridina
ES2128557T3 (es) Derivados de poliamina como agentes radioprotectores.
HU9500559D0 (en) New mercapto-acetamide tricyclic derivatives as enkephalinase-inhibitors
ES2063065T3 (es) Derivados de triazol, procedimiento para su preparacion y composiciones herbicidas que los contienen.
ES2056194T3 (es) Compuestos tetraciclicos antidepresivos.
ES8500259A1 (es) "un metodo para preparar derivados de 3-metilflavona".
FI892222A0 (fi) Peptidalkoholer med antikoagulantverkan.
BG92842A (bg) Метод за получаване на бета-карбонил-карбоксиамиди на 1,3-тиазолидини
ZA872664B (en) Six-membered heterocyclic derivatives of n'-substituted-n,n'-diacylhydrazines
ES8700224A1 (es) Procedimiento para la preparacion de un nuevo derivado de lafenil-3-propeno-2 amina
HU906010D0 (en) New substituted alkyl-piperidine derivatives
JPS5430184A (en) 3,4-dihydrocarbostyril derivative
FR2378518A1 (fr) Nouveaux medicaments a base de derives de tetrahydrodibenzopyranne
SE8100946L (sv) Nya indanderivat, sett att framstella dem, anvendning derav som farmaceutika och farmaceutiska kompositioner som innehaller dess derivat
ATE65986T1 (de) Propanolabkoemmlinge.
SE8504119L (sv) 6-aminometyl-furo-(3,4-c)pyridinderivat, deras framsstellning och farmaceutiska kompositioner innehallande dem